Our retroviral platforms are designed to enable selective delivery of therapeutic genes to cancer cells while sparing healthy tissue. We believe our approach can directly kill cancer cells and selectively activate the immune system against the tumor locally resulting in systemic anticancer activity without the severe autoimmune toxicity commonly seen with other immunotherapy approaches.
In preclinical animal models of brain cancer our lead RRV product candidate, Toca 511 & 5-FC, showed that this cancer killing approach is well tolerated and can result in tumor destruction and prolonged survival in nearly all rodent animals treated. Based on these data we believe Tocagen’s RRV technology platform may be used for the development of treatments for multiple tumor types. This product is advancing through clinical trials.
In human studies, an earlier version of our lead RNV product candidate, Toca Gamma, showed anticancer activity and prolonged survival in humans with stage 4 metastatic melanoma without serious systemic side effects.
Brain Cancer (High Grade Glioma)
Toca 511 & Toca FC